KR20230173265A - Composition With Improved Stability And Transdermal Delivery Rate Of Red Ginseng Oil And Preparing Method Thereof - Google Patents

Abstract

The present invention provides a lipid stabilizing agent comprising a first lipid analog and a solvent; and an oil phase containing red ginseng oil, a second lipid analog, and an emulsifier. It provides a composition with improved stability and transdermal absorption of red ginseng oil. According to the present invention, red ginseng oil can be stabilized by encapsulating it in a lamellar non-aqueous liquid crystalline capsule. As a result, the transdermal absorption rate of red ginseng oil is improved when delivered to the skin, so not only can more bioactive effects be achieved using the same amount of red ginseng oil, but it also has the advantage of being applicable to various product lines such as basic cosmetics and color cosmetics.

Description

Composition with improved stability and transdermal absorption rate of red ginseng oil and method for manufacturing same {Composition With Improved Stability And Transdermal Delivery Rate Of Red Ginseng Oil And Preparing Method Thereof}

The present invention relates to a composition with improved stability and transdermal absorption of red ginseng oil and a method for producing the same.

Ginseng (Panax ginseng C.A. Meyer) is a perennial herb belonging to the genus Panax of the Araliaceae family. It is one of the herbal medicines used in oriental medicine. It has a sweet and bitter taste, has a warm energy, restores vitality and protects the spleen, and It has herbal benefits such as strengthening the lungs.

The main physiologically active substances in ginseng include saponins, also called ginsenosides, essential oil components, polyacetylene, phenolic components, glycosides, and acid peptides. In addition, it contains various components such as vitamins, sugars, and minerals. The general physiological effects of ginseng have been reported to include central nervous system activity, immune function strengthening, and anti-cancer activity. In particular, about 40 types of ginsenosides have been discovered so far, and it has been confirmed that they have a wide range of effects on the central nervous system, endocrine system, immune system, and metabolic system, showing an excellent effect in regulating physical functions, that is, normalizing physiological functions. These ginsenosides may have similar or opposing effects, and it is known that certain ingredients exert various effects alone or through interactions of several types.

Among the nutrients in ginseng, the fat-soluble component content is about 1-2%. Research on the chemical composition and physiological activity of ginseng oil is still insufficient, but according to recent studies, red ginseng oil has specific ingredient characteristics that are differentiated from other existing vegetable oils and is evaluated to have excellent physiological activity. Therefore, research is continuously being conducted to utilize it in cosmetic compositions or functional food compositions (Patent Document 1). However, red ginseng oil has a high polarity, so it is difficult to apply to emulsion-type cosmetic compositions, and it tends to be oxidized by moisture, air, heat, and light, so it has the disadvantage of causing off-odor and discoloration over time.

Accordingly, the present inventors confirmed that the stability of a composition containing red ginseng oil was greatly improved by encapsulating red ginseng oil in a lamellar non-aqueous liquid crystalline capsule and completed the present invention.

Republic of Korea Patent Publication No. 10-1440675 (2014.09.19.)

The purpose of the present invention is to provide a cosmetic composition containing red ginseng oil with improved stability and transdermal absorption as an active ingredient, and a method for producing the same.

One aspect of the present invention is a lipid stabilizing unit comprising a first lipid analog and a solvent; and an oil phase containing red ginseng oil, a second lipid analog, and an emulsifier. It provides a composition with improved stability and transdermal absorption of red ginseng oil.

Another aspect of the present invention includes heating a lipid stabilization unit containing a first lipid analog and a solvent to 75-85°C; Warming the oil phase containing red ginseng oil, a second lipid analog, and an emulsifier to 75-85°C; Adding the oil phase to the lipid stabilization phase and performing primary emulsification; And providing a method for producing a composition with improved stability and transdermal absorption rate of red ginseng oil, comprising: secondary emulsification of the primary emulsion.

According to the present invention, red ginseng oil can be stabilized by encapsulating it in a lamellar non-aqueous liquid crystalline capsule. As a result, the transepidermal absorption rate of red ginseng oil is improved when delivered to the skin, so not only can more bioactive effects be achieved using the same amount of red ginseng oil, but it can also be applied to various product lines such as basic cosmetics and color cosmetics. There are benefits to doing this.

Figure 1 is a schematic diagram showing that the lamellar-type non-aqueous liquid crystalline capsule of the present invention captures red ginseng oil.
Figure 2 is a result confirming that the average particle diameter of the lamellar non-aqueous liquid crystalline capsule of the present invention is uniformly distributed within the range of 200 to 700 nm.
Figure 3 is a graph showing the results of particle size analysis immediately after preparation of the compositions of Comparative Examples 1 to 4.
Figure 4 shows that separation of the composition of Comparative Example 4 occurred after one week at room temperature.

Hereinafter, the present invention will be described in more detail to facilitate understanding of the present invention.

Terms or words used in this specification and claims should not be construed as limited to their usual or dictionary meanings, and the inventor may appropriately define the concept of terms in order to explain his or her invention in the best way. It must be interpreted with meaning and concept consistent with the technical idea of the present invention based on the principle that it is.

1. Composition with improved stability and transdermal absorption of red ginseng oil

One aspect of the present invention is a lipid stabilizing unit comprising a first lipid analog and a solvent; and an oil phase containing red ginseng oil, a second lipid analog, and an emulsifier. It provides a composition with improved stability and transdermal absorption of red ginseng oil.

In the present invention, stability refers to the fact that the lamellar non-aqueous liquid crystalline capsule is formed in a shape of relatively uniform size distribution and the shape is maintained uniformly, and/or the composition for improving the stability and transdermal absorption rate of the red ginseng oil of the present invention is maintained under certain conditions. A layer of oil-phase components to form lamellar-type non-aqueous liquid crystalline capsules and a lipid-stabilizing component to stabilize these lamellar-type non-aqueous liquid-crystalline capsules even after storage (e.g., 45-55°C, for several days to several months) This may mean that separation does not occur and the properties of the composition are maintained.

In the present invention, improving the transdermal absorption rate may mean improving the rate at which a substance penetrating through the skin surface reaches the dermis and spreads.

In the present invention, red ginseng oil can be obtained by separating and extracting the fat-soluble components contained in red ginseng or red ginseng peel through supercritical fluid extraction. Supercritical fluid extraction is an extraction method using a supercritical fluid that appears when the temperature and pressure exceed a certain critical point. The liquid has high dissolving power, rapid material movement and heat transfer, low viscosity, and rapid penetration into micropores due to a high diffusion coefficient. It is an extraction method that combines the advantages of gas and gas. In general, supercritical fluids have the property of changing solubility and density depending on changes in temperature and pressure, so the activity of the extract may vary accordingly. In this way, the extraction method using supercritical fluid allows setting conditions in a high-density state by manipulating pressure and temperature, so it has excellent selectivity for fractionation and separation, allowing high-purity natural active ingredients to be obtained, and can be extracted at a relatively low temperature. Therefore, it has the advantage of preventing loss of natural active ingredients due to heat.

Red ginseng oil is known to have various effects, including wrinkle-improving efficacy, but its high polarity makes it difficult to apply to emulsified cosmetic compositions, and it tends to oxidize due to moisture, air, heat, and light, causing off-odor and off-flavor over time. There was a problem with discoloration occurring. Therefore, in the present invention, red ginseng oil is stabilized by being encapsulated in a lamellar-type non-aqueous liquid crystalline capsule, so that excess red ginseng oil can be used in non-aqueous formulations in solubilized types (skin, essence, ampoule, etc.) and emulsified types (lotions, creams, eye creams, etc.) ) is characterized by being widely applicable to cosmetic compositions.

The red ginseng oil may be included in an amount of 0.1 to 25% by weight, or 5 to 25% by weight, or 7 to 22% by weight, based on the total weight of the composition in which the stability and transdermal absorption rate of the red ginseng oil are improved.

In addition, the lamellar non-aqueous liquid crystalline capsule has a lamellar structure in the form of multiple layers of liquid crystal, similar to intercellular lipids, and is mainly composed of lipid analogs and emulsifiers, and red ginseng oil contains phospholipids that act as emulsifiers. It not only forms part of the lamellar non-aqueous liquid crystalline capsule structure, but is simultaneously encapsulated between the non-polar layers of the lamellar structure. A schematic diagram showing that the lamellar non-aqueous liquid crystalline capsule of the present invention captures red ginseng oil is shown in Figure 1.

The first lipid analog is one selected from the group consisting of lecithin, ceramide, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, sphingomyelin, ganglioside, sphingosine, phytosphingosine, and sphinganine. It may include more. Preferably, the lipid analog includes at least one selected from the group consisting of lecithin, ceramide, and phytosphingosine, and more preferably includes lecithin.

The lecithin may be unsaturated lecithin or saturated lecithin.

The ceramide is a type of sphingolipid in which a fatty acid is linked to a sphingoid base called sphingosine, phytosphingosine, or sphinganine. It is classified into various ceramides depending on the type of fatty acid and sphingoid base. To date, 7 to 9 types of ceramides have been identified in the skin.

The first lipid analog may be included in an amount of 0.5 to 10% by weight, or 3 to 10% by weight, or 5 to 10% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil.

Specifically, when the first lipid analog includes lecithin, lecithin may be included in an amount of 5 to 10% by weight, or 5 to 8% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. If it is below the above numerical range, it is difficult to form a lamellar-type non-aqueous liquid crystalline capsule due to the absence of a cylinder-type emulsifier, which may lead to large particles being formed. If it is above the above numerical range, the hardness increases and the emulsification process is smooth during secondary emulsification with a high-pressure emulsifier. It may not come true.

The solvent may include one or more selected from the group consisting of glycerin, 1,2-hexanediol, 2.3-butanediol, propanediol, ethanol, butylene glycol, 1,3-butylene glycol, and propylene glycol. , preferably glycerin and 1,3-butylene glycol. 1,3-Butylene glycol not only acts as a skin conditioning agent and solvent, but also has a preservative effect.

The solvent is used in an amount of 30 to 98% by weight, or 40 to 97% by weight, or 50 to 96% by weight, or 55 to 80% by weight, or 55 to 77% by weight, based on the total weight of the composition with improved stability and transdermal absorption rate of the red ginseng oil. %, or 60 to 75% by weight.

In particular, when the solvent contains 1,3-butylene glycol, 1,3-butylene glycol is 5 to 95% by weight, or 7 to 70% by weight, based on the total weight of the composition with improved stability and transdermal absorption rate of the red ginseng oil. It may be included in weight percent, or 10 to 60 weight percent, or 30 to 75 weight percent. If 1,3-butylene glycol satisfies the above numerical range, it can exhibit a preservative effect. On the other hand, if 1,3-butylene glycol is below the above numerical range, there is a problem that a preservative must be added separately, and if other polyols (e.g., glycerin) are added, the hardness may increase over time or separation/precipitation phenomenon may occur. You can. If it is included in excess of the above numerical range, the content of red ginseng oil in the composition is reduced, which has the disadvantage of making it difficult to achieve the functionality of red ginseng oil.

In addition, when the solvent contains glycerin, glycerin may be included in an amount of 1 to 40% by weight, or 1.5 to 30% by weight, or 5 to 30% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. there is.

The lipid-stabilizing portion of the present invention may further include a hydrophilic active material. The hydrophilic active material may be an ingredient for imparting functionality to the present invention, for example, for whitening, wrinkle improvement, acne improvement, or irritation relief. For example, it may include one or more selected from the group consisting of steamed ginseng extract, red ginseng extract, portulaca oleracea extract, bottle extract, chamomile flower extract, and chamomile extract. The steaming liquid is a by-product that forms on the surface of ginseng when it is steamed, and contains active ingredients or ginsenosides present on the surface of ginseng.

The hydrophilic active material may be included in an amount of 0.001 to 10% by weight, or 0.1 to 10% by weight, or 0.1 to 7% by weight, or 0.1 to 5% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. .

The second lipid analog is one selected from the group consisting of lecithin, ceramide, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, sphingomyelin, ganglioside, sphingosine, phytosphingosine, and sphinganine. It may include more. Preferably, the second lipid analog includes at least one selected from the group consisting of lecithin, ceramide, and phytosphingosine, and more preferably includes ceramide and phytosphingosine.

The second lipid analog may be included in an amount of 0.01 to 5% by weight, or 0.5 to 5% by weight, or 0.5 to 3% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. If it is below the above numerical range, it may not be easy to form a lamellar non-aqueous liquid crystalline capsule, and if it is above the above numerical range, the hardness may increase and the emulsification process may not be carried out smoothly during secondary emulsification with a high-pressure emulsifier.

In addition, when the second lipid analog includes ceramide, the ceramide is added in an amount of 0.01 to 1% by weight, or 0.05 to 0.7% by weight, or 0.1 to 0.5% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. may be included.

In addition, when the second lipid analog includes phytosphingosine, phytosphingosine is contained in an amount of 0.01 to 2% by weight, or 0.01 to 1.5% by weight, or 0.01 to 1.5% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. It may be included at 0.01 to 1% by weight.

The emulsifiers include polyglyceryl fatty acid ester, polyglyceryl-3, glyceryl stearate, cetyl ethylhexanoate, silicone oils such as dimethicone, cyclomethicone, or phenyltrimethicone, nonpolar oils such as squalene, and polar oils such as squalene. Caprylic/capric triglyceride, and vegetable oils such as olive oil, palm oil, palm kernel oil, palm oil, macadamia nut oil, rice bran oil, sunflower seed oil, camellia oil, avocado oil, soybean oil, and one or more selected from the group consisting of cottonseed oil. may include.

The polyglyceryl fatty acid esters include polyglyceryl-5 laurate, polyglyceryl-5 myristate, polyglyceryl-5 oleate, polyglyceryl-5 stearate, polyglyceryl-10 caprate, and polyglyceryl -10 myristate, polyglyceryl-10 laurate, polyglyceryl-10 oleate, and polyglyceryl-10 stearate, preferably polyglyceryl- May contain 10 myristate.

In the present invention, polyglyceryl-10 myristate is an esterification product of polyglycerin-10 and myristic acid and acts as a skin conditioning agent.

In the present invention, glyceryl stearate is an esterification product of glycerin and stearic acid, is a lipophilic glycerin-based fatty acid emulsifier, and acts as a lubricant on the skin surface.

The emulsifier may be included at 0.05 to 20% by weight, or 0.1 to 18% by weight, or 0.5 to 10% by weight, or 1.5 to 7% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil.

In addition, when the emulsifier includes polyglyceryl-10 myristate, polyglyceryl-10 myristate is 0.5 to 3% by weight, or 0.5 to 2.5% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. It can be included as a percentage. If it is below the above numerical range, the emulsification power may be weak, which may cause problems in forming lamellar non-aqueous liquid crystalline capsules. If it is above the above numerical range, the hardness may increase and the emulsification process may not be carried out smoothly during secondary emulsification with a high-pressure emulsifier.

In addition, when the emulsifier includes polyglyceryl-3, polyglyceryl-3 is 0.5 to 5% by weight, 0.5 to 3.5% by weight, or 1 to 1% by weight relative to the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. It may be included at 3.5% by weight, or 1 to 2.5% by weight. If it is below the above numerical range, the emulsification power may be weak, which may cause problems in forming lamellar non-aqueous liquid crystalline capsules. If it is above the above numerical range, the hardness may increase and the emulsification process may not be carried out smoothly during secondary emulsification with a high-pressure emulsifier.

In addition, when the emulsifier includes glyceryl stearate, glyceryl stearate may be included in an amount of 0.1 to 2% by weight, or 0.3 to 1.3% by weight, based on the total weight of the composition with improved stability and transdermal absorption of the red ginseng oil. If it is below the above numerical range, the emulsification power may be weak, which may cause problems in forming lamellar non-aqueous liquid crystalline capsules. If it is above the above numerical range, the hardness may increase and the emulsification process may not be carried out smoothly during secondary emulsification with a high-pressure emulsifier.

In addition, the composition with improved stability and transdermal absorption rate of red ginseng oil of the present invention can be used to manufacture cosmetic compositions.

The cosmetic composition contains the composition with improved stability and transdermal absorption rate of red ginseng oil of the present invention in an amount of 0.1 to 30% by weight, or 1 to 30% by weight, or 1 to 20% by weight, based on a total of 100% by weight of the cosmetic composition. It may contain 2 to 15% by weight, or 2.5 to 12% by weight, or 3 to 10% by weight, or 3 to 7% by weight.

The cosmetic composition can be prepared in liquid or solid form using bases, auxiliaries and additives commonly used in the cosmetics field. Cosmetics in liquid or solid form may include, but are not limited to, cosmetics such as lotions, creams, lotions, and bath salts.

Bases, auxiliaries and additives commonly used in the cosmetics field are not particularly limited and include, for example, water, alcohol, propylene glycol, stearic acid, glycerol, cetyl alcohol, liquid paraffin, etc.

When manufacturing a cosmetic composition using a composition with improved stability and transdermal absorption of the red ginseng oil of the present invention, the cosmetic composition is typically used in cosmetic compositions as well as the composition with improved stability and transdermal absorption of the red ginseng oil of the present invention. The ingredients used may include, for example, antioxidants, stabilizers, solubilizers, vitamins, conventional auxiliaries such as pigments and flavors, and carriers.

The cosmetic composition can be prepared in any formulation commonly prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil. , may be formulated as powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, flexible lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, powder, hair tonic, hair lotion, hair cream, hair spray, hair. Mousse, hair gel, hair conditioner, hair shampoo, hair rinse, hair pack, hair treatment, shampoo for pets, rinse for pets, hand cream, hand sanitizer, detergent, soap, disinfectant, wet wipes, mask, ointment, patch. Alternatively, it may be manufactured in the form of a filter filler.

When the formulation of the cosmetic composition is paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier ingredients. It can be.

When the formulation of the cosmetic composition is powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient. In particular, in the case of spray, chlorofluorohydrocarbon, May contain propellants such as propane/butane or dimethyl ether.

When the formulation of the cosmetic composition is a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, These include 1,3-butylene glycol oil, fatty esters of glycerol, fatty acid esters of polyethylene glycol or sorbitan.

When the formulation of the cosmetic composition is a suspension, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and miso. Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.

When the formulation of the cosmetic composition is a surfactant-containing cleansing agent, the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, Alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester can be used.

The cosmetic composition may be used alone or in multiple applications, or may be used in multiple applications with other cosmetic compositions. In addition, the cosmetic composition can be used according to the usual usage method, and the number of times of use can be varied depending on the user's skin condition or preference.

If the cosmetic composition is a soap, a surfactant-containing cleansing formulation, or a surfactant-free cleansing formulation, it can be applied to the skin and then wiped off, removed, or washed with water. As a specific example, the soap is liquid soap, powdered soap, solid soap, and oil soap, the surfactant-containing cleansing formulation is cleansing foam, cleansing water, cleansing towel, and cleansing pack, and the surfactant-free cleansing formulation is cleansing cream. , cleansing lotion, cleansing water and cleansing gel, but are not limited thereto.

2. Method for producing a composition with improved stability and transdermal absorption of red ginseng oil

Another aspect of the present invention includes heating a lipid stabilization unit containing a first lipid analog and a solvent to 75-85°C; Warming the oil phase containing red ginseng oil, a second lipid analog, and an emulsifier to 75-85°C; Adding the oil phase to the lipid stabilization phase and performing primary emulsification; And providing a method for producing a composition with improved stability and transdermal absorption rate of red ginseng oil, comprising: secondary emulsification of the primary emulsion.

First, the lipid stability unit containing the first lipid analog and the solvent is heated to 75-85°C. Preferably, the temperature may be 80-85°C.

Next, the oil phase containing red ginseng oil, second lipid analog, and emulsifier is heated to 75-85°C. Preferably, the temperature may be 80-85°C.

Since the detailed description of the lipid stabilizing part, oil phase part, red ginseng oil, first lipid analogue, second lipid analogue, emulsifier and solvent can be applied as described above, detailed description is omitted here.

The oil phase is added to the lipid stabilization phase and first emulsified. At this time, primary emulsification can be performed by stirring at 2500-3500 rpm at 75-85°C. Preferably, the temperature may be 80 to 85° C., and the stirring time may be 1 to 7 minutes, or 3 to 5 minutes. For stirring, common equipment such as a homomixer or aji mixer can be used, and a homomixer is preferably used. The homomixer sucks materials between the rotors by the vacuum around the rotor generated by the high-speed rotation of the rotor, and emulsifies, uniformly, and disperses them in the minute gap between the rotor and the stator, and fills the hole in the upper part of the stator. It is preferable to use in the present invention a high-speed emulsification disperser through which the treated material is discharged.

Thereafter, the primary emulsion is cooled to 20-60°C, 30-60°C, or 45-55°C while stirring, and then placed in an emulsifier for secondary emulsification. The secondary emulsification can be performed at 700 to 1700 bar using a high-pressure emulsifier. Preferably, the pressure may be 1000 to 1500 bar. At this time, a high-pressure emulsifier may be used, but is not particularly limited thereto. High-pressure emulsifiers change the high pressure to high speed as very high pressure from a pressure pump passes through an interaction chamber made of fine-sized diamonds, and use a type of vacuum phenomenon called cavitation within the interaction chamber to create nano-sized emulsifiers. As an equipment capable of making particles, it is preferable for use in the present invention because the force for pulverizing the particles is much stronger than that of a conventional mixer such as a homomixer.

Hereinafter, the present invention will be described in detail by examples.

However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited by the following examples.

Example

Example 1

After adding the lipid stabilization part as shown in Table 1 below into a vacuum emulsification tank capable of temperature control and stirring, it is heated to a temperature of 80 to 85°C after mixing, and the oil phase is placed in a separate dissolution tank that allows temperature control and stirring. It was prepared by heating it to 80~85℃. After adding the oil phase to the lipid stabilization part and first emulsifying it at 80~85℃ (HOMO MIXER, 3000rpm, 5 minutes), cooling it to 50℃ while stirring with a paddle, and putting it into a high-pressure emulsifier (MICROFLUIDIZER LM20, USA) and emulsifying for 1,000 minutes. A lamellar non-aqueous liquid crystalline capsule composition was prepared by secondary emulsification by treating the mixture three times at a pressure of ~1,500 bar.

Examples 2 to 3 and Comparative Examples 1 to 4

Lamellar-type non-aqueous liquid crystalline capsule compositions of Examples 2 to 3 and Comparative Examples 1 to 4 were prepared in the same manner as Example 1, except that each component and content were changed as shown in Table 1 below.

division Ingredient name Example 1 Example 2 Example 3 Comparative Example 1 Comparative example 2 Comparative Example 3 Comparative example 4 Ministry of Geological Stability 1,3-butylene glycol 57.2 38.5 72.0 - 58.7 59.7 54.2 glycerin 10 30 5 67.2 10 10 10 lecithin 8 5 10 8 8 8 15 Irritation Relief Extract 0.1 0.1 0.1 0.1 0.1 0.1 0.1 paid part Polyglyceryl-10 Myristate 1.5 2 0.9 1.5 - 1.5 - polyglyceryl-3 2.5 3.5 1.5 2.5 2.5 - - glyceryl stearate 0.5 0.7 0.3 0.5 0.5 0.5 0.5 Phytosphingosine 0.1 0.1 0.1 0.1 0.1 0.1 0.1 ceramide 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Red ginseng oil 20 20 10 20 20 20 20

Experimental Example 1

The distribution and size of particles were analyzed using a particle size analyzer (MALVERN PANALYTICAL Mastersizer 3000, UK). In particular, the results of analyzing the distribution and size of particles for the composition of Example 1 are shown in Figure 2, and the results for the compositions of Comparative Examples 1 to 4 are shown in Figure 3.

In addition, immediately after preparing each composition, it was placed in a 45 ml vial, and the stability of 50°C, room temperature, 5°C, 40°C, and CYC (-5°C to 45°C, 4 cycles per day) was observed with the naked eye. Among these, the results for 50°C, the most severe condition, are shown in Table 2 below.

Additionally, particle size was measured after 1 week and 1 month at room temperature. However, in the case of the comparative example compositions, separation occurred at high temperature (50°C), so the particle size at room temperature was not measured.

Measurement sample Example 1 Example 2 Example 3 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Particle size (average) 350㎚ 300㎚ 500㎚ not measurable uneven uneven 700㎚~2㎛ unevenness Stability for 1 week (50℃) ○ ○ ○ X X X X 1 month stability (50℃) ○ ○ △ X X X X Particle size after 1 week 350㎚ 350㎚ 500㎚ - - - - Particle size after 1 month 400㎚ 350㎚ 600㎚ - - - -

○ (very good), △ (good), X (separate)

From the results in Table 2, it can be seen that the stability of the lamellar non-aqueous liquid crystalline capsule composition prepared according to the examples of the present invention is improved.

On the other hand, in the case of Comparative Example 1 in which the glycerin content was increased without using 1,3-butylene glycol, the hardness increased too much after the first emulsification, making high-pressure emulsification treatment difficult, and even if the temperature was raised, all temperatures A turbulent precipitation phenomenon occurred. In addition, the composition of Comparative Example 1 showed a relatively uniform particle size distribution immediately after production (FIG. 3a), but particle size measurement was impossible after a week due to decreased stability.

Additionally, in the case of Comparative Example 2 in which polyglyceryl-10 myristate was not used, separation occurred at high temperature (50°C).

Additionally, in the case of Comparative Example 3 in which polyglyceryl-3 was not used, separation occurred at high temperature (50°C) and precipitation occurred at low temperature (5°C).

In addition, in the case of Comparative Example 4, in which neither polyglyceryl-10 myristate nor polyglyceryl-3 was used, but instead the lecithin content was increased, red ginseng oil oozed out at both room temperature and high temperature (50°C). . Figure 4 shows a photograph of the appearance of the composition of Comparative Example 4 after it was stored at room temperature for a week, from which it can be seen that red ginseng oil oozed out and separation occurred.

Experimental Example 2

In order to measure the transdermal absorption, 1.0 g of the composition of Example 1 was applied to an artificial skin cell (Merck, USA) using a dissolution tester (PERME GEAR V3A-02, USA), filled with ethanol, and maintained at 36°C. After 24 hours, the elution amount was measured using high-performance liquid chromatography (LC). For the compositions of Examples and Comparative Examples, the eluted amount (%) of linolenic acid in red ginseng oil was calculated based on the amount eluted compared to the input amount, and the results are shown in Table 3.

division Dissolution amount (%) Example 1 73.2 Example 2 80.9 Example 3 81.4 Comparative Example 1 - Comparative Example 2 79.8 Comparative Example 3 68.8 Comparative Example 4 41.7

In Table 3, it can be seen that the example composition has a higher dissolution amount (%) than the comparative example composition, so the transdermal absorption rate of red ginseng oil is improved in the example composition.

On the other hand, Comparative Example 1 was not measured because it had high hardness and could not be processed with a high-pressure emulsifier. In the case of Comparative Example 2, the melting amount is slightly lower than that of the Example, but as seen above, there is a problem in that the stability of the lamellar non-aqueous liquid crystalline capsule composition is low. In addition, it can be seen that in Comparative Examples 3 and 4, the melting amount decreases compared to the Example.

Preparation Example 1 - Skin

Phases A and B of Table 4 were dispersed using an AGI MIXER and then neutralized by adding phase C. After adding phase D to phases A to C and dispersing them evenly with an aji mixer, phase E was added and completely dispersed with an aji mixer, followed by defoaming.

Preparation Example 2 - Essence

Phases A and B of Table 4 were dispersed using an aji mixer and then neutralized by adding phase C. After adding phase D to phases A to C and dispersing them evenly with an aji mixer, phase E was added and completely dispersed with an aji mixer, followed by defoaming.

Preparation Example 3 - Ampoule

Phases A and B of Table 4 were dispersed using an aji mixer and then neutralized by adding phase C. After adding phase D to phases A to C and dispersing them evenly with an aji mixer, phases E and F were added and completely dispersed with an aji mixer, followed by defoaming.

division Ingredient name skin essence ample A Purified water
(or red ginseng condensate) TO 100 TO 100 TO 100 glycerin 5 10 20 1,2-hexadiol 2 2 2 B carbomer 0.1 0.15 0.20 Sodium Hyaluronate 0.1 0.5 0.7 C Tromethamine 0.04 0.08 0.04 D 1,3-butylene glycol 5 5 5 Solubilizer 0.5 0.5 0.7 incense 0.07 0.07 0.07 Dimethicone 0 0 0.5 E Example 1 10 10 10 F polymethylsilsesquioxane 0 0 3

Preparation Example 4 - Lotion

Phases A and B of Table 5 were dispersed with an aji mixer and then dissolved by heating. Phase C was added to a separate dissolution tank and then dissolved by heating. Phase C was added to the A+B phase and then first emulsified, and phase D After neutralizing by adding, it was cooled to 50°C, phase E was added, secondary emulsification was done, and then cooled to 33°C.

Preparation Example 5 - Cream

Phases A and B of Table 5 were dispersed with an aji mixer and then dissolved by heating. Phase C was added to a separate dissolution tank and then dissolved by heating. Phase C was added to the A+B phase and then first emulsified, and phase D After neutralizing by adding, it was cooled to 50°C, phase E was added, secondary emulsification was done, and then cooled to 33°C.

Preparation Example 6 - Eye Cream

Phases A and B of Table 5 were dispersed with an aji mixer and then dissolved by heating. Phase C was added to a separate dissolution tank and then dissolved by heating. Phase C was added to the A+B phase and then first emulsified, and phase D After neutralizing by adding, it was cooled to 50°C, phase E was added, secondary emulsification was done, and then cooled to 33°C.

division Ingredient name Lotion cream eye cream A Purified water TO 100 TO 100 TO 100 glycerin 20 10 15 B carbomer 0.15 0.20 0.25 C Polyglyceryl-3 0.5 1.0 2.0 Glycelistearate 0.7 1.0 1.0 cetyl alcohol 0.5 1.0 1.5 Sorbitan Oliveade 1.0 2.0 2.0 mango butter 0 One 3 shea butter 0 One 5 Jojoba oil 0 5 2 Dimethicone 5 2 5 Cyclomethicone 2 2 2 squalene 2 2 3 Caprylic/Capric Triglyceride One 2 2 D Tromethamine 0.12 0.16 0.20 E Example 1 10 10 20

Experimental Example 3

Immediately after preparing the 7 types of solubilized and emulsified cosmetic compositions of Preparation Examples 1 to 6, Stability was observed with the naked eye, and the results are shown in Table 6 below.

division Formulation 25℃ 5℃ CYC 40℃ 50℃ Solubilization Skin (low viscosity) ◎ ◎ X X X Skin (gel) ◎ ◎ ○ ○ ○ essence ◎ ◎ ○ ○ ○ ample ◎ ◎ ○ ○ ○ oil paint Lotion ◎ ◎ ◎ ◎ ◎ cream ◎ ◎ ◎ ◎ ◎ eye cream ◎ ◎ ◎ ◎ ◎

◎ Very good, ○ Good,

The low-viscosity skin formulation without a thickener had a high specific gravity due to the nature of non-aqueous liquid crystals, so precipitation occurred at high temperature after 2 days. However, it was confirmed that the gel skin formulation with the addition of a thickener had improved precipitation and good stability.

Claims (12)

A lipid stabilizing unit comprising a first lipid analog and a solvent; and
A composition with improved stability and transdermal absorption of red ginseng oil, comprising: an oil phase comprising red ginseng oil, a second lipid analog, and an emulsifier. In claim 1,
The first lipid analog and the second lipid analog are each composed of lecithin, ceramide, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, sphingomyelin, ganglioside, sphingosine, phytosphingosine, and sphinganine. A composition with improved stability and transdermal absorption of red ginseng oil containing one or more species selected from the group. In claim 1,
The emulsifiers include polyglyceryl-5 laurate, polyglyceryl-5 myristate, polyglyceryl-5 oleate, polyglyceryl-5 stearate, polyglyceryl-10 caprate, and polyglyceryl-10 myristate. , polyglyceryl-10 laurate, polyglyceryl-10 oleate, polyglyceryl-10 stearate, polyglyceryl-3, glyceryl stearate, cetylethylhexanoate, dimethicone, cyclomethicone, phenyl. 1 selected from the group consisting of trimethicone, squalene, caprylic/capric triglyceride, olive oil, palm oil, palm kernel oil, palm oil, macadamia nut oil, rice bran oil, sunflower seed oil, camellia oil, avocado oil, soybean oil and cottonseed oil. A composition containing improved stability and transdermal absorption of red ginseng oil containing more than one species. In claim 1,
The solvent is red ginseng oil containing at least one selected from the group consisting of glycerin, 1,2-hexanediol, 2.3-butanediol, propanediol, ethanol, butylene glycol, 1,3-butylene glycol, and propylene glycol. A composition with improved stability and transdermal absorption rate. In claim 1,
The lipid stabilization part is the stability of red ginseng oil, which further contains a hydrophilic active substance including one or more selected from the group consisting of steamed ginseng extract, red ginseng extract, portulaca oleracea extract, centella asiatica extract, chamomile flower extract, and chamomile extract, and A composition with improved transdermal absorption rate. In claim 1,
Based on the total weight of the composition with improved stability and transdermal absorption of red ginseng oil,
Red heart oil 0.1~25% by weight;
0.5-10% by weight of the first lipid analog;
0.5-5% by weight of second lipid analog;
Emulsifier 0.5-10% by weight; and
A composition with improved stability and transdermal absorption of red ginseng oil containing 40 to 97% by weight of solvent. In claim 1,
Based on the total weight of the composition with improved stability and transdermal absorption of red ginseng oil,
Red heart oil 0.1~25% by weight;
0.5-10% by weight of the first lipid analog;
0.5-5% by weight of second lipid analog;
Emulsifier 0.5-10% by weight; and
Contains 50 to 96% by weight of solvent;
The solvent contains 5 to 95% by weight of 1,3-butylene glycol,
The emulsifier is a composition with improved stability and transdermal absorption of red ginseng oil containing 0.5 to 2.5% by weight of polyglyceryl-10 myristate, 1 to 3.5% by weight of polyglyceryl-3, and 0.1 to 2% by weight of glyceryl stearate. . Heating the lipid stabilization unit containing the first lipid analog and the solvent to 75-85°C;
Warming the oil phase containing red ginseng oil, a second lipid analog, and an emulsifier to 75-85°C;
Adding the oil phase to the lipid stabilization phase and performing primary emulsification; and
A method for producing a composition with improved stability and transdermal absorption of red ginseng oil, comprising: secondary emulsification of the primary emulsion. In claim 8,
The first lipid analog and the second lipid analog are each composed of lecithin, ceramide, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, sphingomyelin, ganglioside, sphingosine, phytosphingosine, and sphinganine. A method comprising one or more species selected from the group. In claim 8,
The emulsifiers include polyglyceryl-5 laurate, polyglyceryl-5 myristate, polyglyceryl-5 oleate, polyglyceryl-5 stearate, polyglyceryl-10 caprate, and polyglyceryl-10 myristate. , polyglyceryl-10 laurate, polyglyceryl-10 oleate, polyglyceryl-10 stearate, polyglyceryl-3, glyceryl stearate, cetylethylhexanoate, dimethicone, cyclomethicone, phenyl. 1 selected from the group consisting of trimethicone, squalene, caprylic/capric triglyceride, olive oil, palm oil, palm kernel oil, palm oil, macadamia nut oil, rice bran oil, sunflower seed oil, camellia oil, avocado oil, soybean oil and cottonseed oil How to include more than one species. In claim 8,
The solvent includes at least one selected from the group consisting of glycerin, 1,2-hexanediol, 2.3-butanediol, propanediol, ethanol, butylene glycol, 1,3-butylene glycol, and propylene glycol. In claim 8,
The secondary emulsification is performed at 1000 to 1500 bar using a high-pressure emulsifier.

Images